NSABP B-41: A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
RNA-seq (gene expression) · human · 245 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Breast cancerThis series is part of our curated briefing on it.
- Samples
- 245 samples: 245 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 TrialsJAMA oncology · 2024
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE234519_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA981574. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 245 sample titles: 245 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7469940 B41_66_NS01_BX_S71
- GSM7469941 B41_69_E_BX_S73
- GSM7469942 B41_51_A_BX_S57
- GSM7469943 B41_40_B_BX_S54
- GSM7469944 B41_22_NS01_BX_S53
- GSM7469945 B41_70_B1_BX_S74
- GSM7469946 B41_67_A1_BX_S72
- GSM7469947 B41_15_A1_BX_S50
- GSM7469948 B41_63_A_BX_S60
- GSM7469949 B41_19_15_BX_S37
- GSM7469950 B41_16_1_BX_S51
- GSM7469951 B41_46_A1_BX_S64
- GSM7469952 B41_57_X3_BX_S59
- GSM7469953 B41_56_A1_BX_S67
- GSM7469954 B41_26_NS01_BX_S55
- GSM7469955 B41_75_A1_BX_S77
- GSM7469956 B41_23_A1_BX_S49
- GSM7469957 B41_24_NS01_BX_S50
- GSM7469958 B41_25_1_BX_S54
- GSM7469959 B41_37_A1_BX_S59
- GSM7469960 B41_29_A1_BX_S38
- GSM7469961 B41_27_A1_BX_S56
- GSM7469962 B41_36_2_BX_S58
- GSM7469963 B41_35_A1_BX_S57
- GSM7469964 B41_48_A1_BX_S65
- GSM7469965 B41_31_A08_BX_S39
- GSM7469966 B41_30_B_BX_S53
- GSM7469967 B41_47_NS01_BX_S56
- GSM7469968 B41_18_X3_BX_S52
- GSM7469969 B41_50_B_BX_S66
- GSM7469970 B41_39_NS01_BX_S61
- GSM7469971 B41_38_A_BX_S60
- GSM7469972 B41_42_5_BX_S62
- GSM7469973 B41_62_2_BX_S68
- GSM7469974 B41_76_A1_BX_S78
- GSM7469975 B41_43_NS01_BX_S63
- GSM7469976 B41_64_A1_BX_S69
- GSM7469977 B41_77_1_BX_S79
- GSM7469978 B41_65_B_BX_S70
- GSM7469979 B41_72_1_BX_S75
+ 205 more — browse all 245 samples with per-sample file links →
- GSE104193 Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signalling and malignant features in vitro and in vivo 32 samples same disease briefing
- GSE104675 Role for the Transcriptional Activator ZRF1 in Breast Cancer Progression and Endocrine Resistance 6 samples same disease briefing
- GSE10885 An integromic analysis reveals that metaplastic carcinomas are distinct from basal-like tumors. 244 samples same disease briefing
- GSE10886 A Supervised Risk Predictor of Breast Cancer Based on Biological Subtypes 226 samples same disease briefing
- GSE11121 The humoral immune system has a key prognostic impact in node-negative breast cancer 200 samples same disease briefing
- GSE275065 NSABP B-41: A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer [B41_27_POST] 27 samples shares nsabp, b-41, her2, combination, trastuzumab, paclitaxel, lapatinib, followed
- GSE264120 Trastuzumab-associated cardiotoxicity in Patient Specific iPSC-derived cardiomyocytes from HER2+ breast cancer patients 74 samples shares her2, trastuzumab
- GSE243375 HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial 287 samples shares her2
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.